Thousand Oaks biotech giant Amgen entered a crowded field with its rheumatoid arthritis biosimilar Avsola, where it will tussle with three competitors for some $6 billion in annual sales. The move is the latest in its biosimilar strategy, playing to the biotech giant’s strength in the anti-inflammatory field and targeting newer patients in a growing…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
